Please login to the form below

Not currently logged in
Email:
Password:

Shire acts against Sandoz and Amneal

Shire is taking legal action against Amneal and Sandoz for patent infringements

Shire has filed lawsuits in the US District Court for the District of New Jersey against each of Amneal Pharmaceuticals and Sandoz for infringement of Shire's VYVANSE patents.

The lawsuits were initiated in response to abbreviated new drug applications filed by Amneal and Sandoz seeking US Food and Drug Administration (FDA) approval to market and sell generic versions of all currently approved doses of VYVANSE.

Under the Hatch-Waxman Act, the FDA must refrain from approving the Sandoz and Amneal ANDAs for 30 months (expiring August 23, 2014), or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier.

Sandoz declined to comment, while Amneal was unavailable to comment at the time of writing.

4th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics